Diagnostic predictors of Legionella pneumonia in Japan

Naoyuki Miyashita; Nobuyuki Horita; Futoshi Higa; Yosuke Aoki; Toshiaki Kikuchi; Masafumi Seki; Kazuhiro Tateda; Nobuko Maki; Kazuhiro Uchino; Kazuhiko Ogasawara; Hiroshi Kiyota; Akira Watanabe

doi:10.1016/j.jiac.2017.12.009

Diagnostic predictors of Legionella pneumonia in Japan

Naoyuki Miyashita, Nobuyuki Horita, Futoshi Higa, Yosuke Aoki, Toshiaki Kikuchi, Masafumi Seki, Kazuhiro Tateda, Nobuko Maki, Kazuhiro Uchino, Kazuhiko Ogasawara, Hiroshi Kiyota, Akira Watanabe

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	159-163
Number of pages	5
Journal	Journal of Infection and Chemotherapy
Volume	24
Issue number	3
DOIs	https://doi.org/10.1016/j.jiac.2017.12.009
Publication status	Published - 2018 Mar

Keywords

C-reactive protein
Community-acquired pneumonia
Diagnostic predictors
Legionella
Serum sodium

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jiac.2017.12.009

Cite this

Diagnostic predictors of Legionella pneumonia in Japan. / Miyashita, Naoyuki; Horita, Nobuyuki; Higa, Futoshi; Aoki, Yosuke; Kikuchi, Toshiaki; Seki, Masafumi; Tateda, Kazuhiro; Maki, Nobuko; Uchino, Kazuhiro; Ogasawara, Kazuhiko; Kiyota, Hiroshi; Watanabe, Akira.

In: Journal of Infection and Chemotherapy, Vol. 24, No. 3, 03.2018, p. 159-163.

Research output: Contribution to journal › Article › peer-review

@article{bd09f3cacb814490803ebd2061ba14ac,

title = "Diagnostic predictors of Legionella pneumonia in Japan",

keywords = "C-reactive protein, Community-acquired pneumonia, Diagnostic predictors, Legionella, Serum sodium",

author = "Naoyuki Miyashita and Nobuyuki Horita and Futoshi Higa and Yosuke Aoki and Toshiaki Kikuchi and Masafumi Seki and Kazuhiro Tateda and Nobuko Maki and Kazuhiro Uchino and Kazuhiko Ogasawara and Hiroshi Kiyota and Akira Watanabe",

note = "Funding Information: Akira Watanabe has received speaker honoraria from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., UCB Japan Co. Ltd., AbbVie GK, and GlaxoSmithKline K.K.; donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.; payments for manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Fujifilm Pharma Co., Ltd., and Meiji Seika Pharma Co., Ltd. Funding Information: Toshiaki Kikuchi has received grant support from Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Inc., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Funding Information: Yosuke Aoki has received speaker honoraria from MSD K.K., Shionogi & Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; and grant support from Shionogi & Co., Ltd. Funding Information: Kazuhiro Tateda has received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; research funding from Otsuka Pharmaceutical Co., Ltd., grant support from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Japan Blood Products Organization, Asahi Kasei Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., and Toyama Pharmaceutical Co., Ltd.; and donations from Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and MSD K.K. ",

year = "2018",

month = mar,

doi = "10.1016/j.jiac.2017.12.009",

language = "English",

volume = "24",

pages = "159--163",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Diagnostic predictors of Legionella pneumonia in Japan

AU - Miyashita, Naoyuki

AU - Horita, Nobuyuki

AU - Higa, Futoshi

AU - Aoki, Yosuke

AU - Kikuchi, Toshiaki

AU - Seki, Masafumi

AU - Tateda, Kazuhiro

AU - Maki, Nobuko

AU - Uchino, Kazuhiro

AU - Ogasawara, Kazuhiko

AU - Kiyota, Hiroshi

AU - Watanabe, Akira

N1 - Funding Information: Akira Watanabe has received speaker honoraria from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., UCB Japan Co. Ltd., AbbVie GK, and GlaxoSmithKline K.K.; donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.; payments for manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Fujifilm Pharma Co., Ltd., and Meiji Seika Pharma Co., Ltd. Funding Information: Toshiaki Kikuchi has received grant support from Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Inc., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Funding Information: Yosuke Aoki has received speaker honoraria from MSD K.K., Shionogi & Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; and grant support from Shionogi & Co., Ltd. Funding Information: Kazuhiro Tateda has received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; research funding from Otsuka Pharmaceutical Co., Ltd., grant support from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Japan Blood Products Organization, Asahi Kasei Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., and Toyama Pharmaceutical Co., Ltd.; and donations from Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and MSD K.K.

PY - 2018/3

Y1 - 2018/3

KW - C-reactive protein

KW - Community-acquired pneumonia

KW - Diagnostic predictors

KW - Legionella

KW - Serum sodium

UR - http://www.scopus.com/inward/record.url?scp=85041524239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041524239&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2017.12.009

DO - 10.1016/j.jiac.2017.12.009

M3 - Article

AN - SCOPUS:85041524239

VL - 24

SP - 159

EP - 163

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 3

ER -

Diagnostic predictors of Legionella pneumonia in Japan

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this